StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $85.47 | $86.71 | +1.45% | 0.5M |
| 05-11 | $86.62 | $87.12 | +0.58% | 0.3M |
| 05-12 | $86.93 | $86.15 | -0.90% | 0.3M |
| 05-13 | $85.36 | $85.74 | +0.45% | 0.4M |
| 05-14 | $85.48 | $85.34 | -0.16% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $2.04M | $1.75M | $1.36M | $1.16M |
Operating Income | $-177.93M | $-108.39M | $-68.10M | $-33.18M |
Net Income | $-162.34M | $-97.91M | $-31.63M | $-29.51M |
EPS (Diluted) | $-4.20 | $-2.68 | $-1.71 | $-0.82 |
Total Assets | $530.92M | $577.45M | $326.08M | $348.58M |
Total Liabilities | $37.52M | $30.99M | $23.00M | $19.97M |
Cash & Equivalents | $51.09M | $55.98M | $13.24M | $10.12M |
Free Cash Flow OCF − CapEx | $-129.27M | $-82.15M | $-51.59M | $-27.65M |
Shares Outstanding | 43.22M | 42.85M | 32.18M | 32.13M |
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
DNTH is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.